Lawmaker accuses Hanmi, Drug Ministry of falsehoods
Oct 7, 2016
[THE INVESTOR] Hanmi Pharmaceutical was aware of the negative side effects of targeted cancer therapy Olmutinib in August, an opposition lawmaker claimed on Oct. 7.Rep. Jung Choun-sook of the main opposition Minjoo Party of Korea revealed a document from Boehringer Ingelheim informing Hanmi of canceling all clinical trials sent on Aug. 23. In the statement, Boehringer Ingelheim stated that patients will not be recruited for tests, and that ongoing tests will be halted according to recommendation